336 related articles for article (PubMed ID: 9677461)
1. Evaluation on serum 2'-5'oligoadenylate synthetase (2'-5'oligoAS) and beta 2 microglobulin (B2M) in patients with nodal metastases from cutaneous malignant melanoma treated with rIFN-alpha 2A.
Martinetti A; Seregni E; Belli F; Mazzocchi A; Agresti R; Cascinelli N; Greco M; Bombardieri E
Anticancer Res; 1998; 18(3B):2027-30. PubMed ID: 9677461
[TBL] [Abstract][Full Text] [Related]
2. Combination of highly purified human leukocyte interferon alpha and 13-cis-retinoic acid for the treatment of metastatic melanoma.
Fierlbeck G; Schreiner T; Rassner G
Cancer Immunol Immunother; 1995 Mar; 40(3):157-64. PubMed ID: 7728774
[TBL] [Abstract][Full Text] [Related]
3. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.
Cascinelli N; Belli F; MacKie RM; Santinami M; Bufalino R; Morabito A
Lancet; 2001 Sep; 358(9285):866-9. PubMed ID: 11567700
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma.
Kirkwood JM; Resnick GD; Cole BF
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S16-23. PubMed ID: 9122729
[TBL] [Abstract][Full Text] [Related]
5. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.
Kleeberg UR; Suciu S; Bröcker EB; Ruiter DJ; Chartier C; Liénard D; Marsden J; Schadendorf D; Eggermont AM;
Eur J Cancer; 2004 Feb; 40(3):390-402. PubMed ID: 14746858
[TBL] [Abstract][Full Text] [Related]
6. Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma.
Hofmann MA; Kiecker F; Küchler I; Kors C; Trefzer U
J Cancer Res Clin Oncol; 2011 Mar; 137(3):455-62. PubMed ID: 20454974
[TBL] [Abstract][Full Text] [Related]
7. 2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C.
Giannelli G; Antonelli G; Fera G; Dianzani F; Schiraldi O
J Interferon Res; 1993 Feb; 13(1):57-60. PubMed ID: 8454912
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma.
Fierlbeck G; Ulmer A; Schreiner T; Stroebel W; Schiebel U; Brzoska J
J Interferon Cytokine Res; 1996 Oct; 16(10):777-81. PubMed ID: 8910762
[TBL] [Abstract][Full Text] [Related]
9. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy.
Lesinski GB; Valentino D; Hade EM; Jones S; Magro C; Chaudhury AR; Walker MJ; Carson WE
Cancer Immunol Immunother; 2005 Sep; 54(9):815-25. PubMed ID: 15668815
[TBL] [Abstract][Full Text] [Related]
10. Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma.
Castello G; Comella P; Manzo T; Napolitano M; Parziale AP; Galati MG; Daponte A; Casaretti R; Celentano E; Comella G
Melanoma Res; 1993 Feb; 3(1):43-9. PubMed ID: 8471836
[TBL] [Abstract][Full Text] [Related]
11. Serum 2',5'-oligoadenylate synthetase concentrations in acute and chronic hepatitis C.
Yang PM; Wang JT; Chiang BL; Lai MY; Chen DS
J Formos Med Assoc; 1997 May; 96(5):314-9. PubMed ID: 9170817
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma.
Eton O; Talpaz M; Lee KH; Rothberg JM; Brell JM; Benjamin RS
Cancer; 1996 Mar; 77(5):893-9. PubMed ID: 8608480
[TBL] [Abstract][Full Text] [Related]
13. The role of interferon alfa in the treatment of metastatic melanoma.
Legha SS
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S24-31. PubMed ID: 9122731
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
15. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative.
Russo D; Candoni A; Grattoni R; Minisini R; Rosti G
Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589
[TBL] [Abstract][Full Text] [Related]
16. Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b.
Fuchs D; Norkrans G; Wejstal R; Reibnegger G; Weiss G; Weiland O; Schvarcz R; Fryden A; Wachter H
Eur J Med; 1992; 1(4):196-200. PubMed ID: 1341444
[TBL] [Abstract][Full Text] [Related]
17. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
[TBL] [Abstract][Full Text] [Related]
19. Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C.
Solinas A; Cossu P; Poddighe P; Tocco A; Deplano A; Garrucciu G; Diana MS
Liver; 1993 Oct; 13(5):253-8. PubMed ID: 8259037
[TBL] [Abstract][Full Text] [Related]
20. Serum 2'-5'oligoadenylate synthetase as a monitoring marker of anti-viral effect during interferon therapy for chronic type B hepatitis.
Karino Y; Sugawara T; Saga A; Yoshida J; Matsushima T; Miyazaki T; Toyota J; Okuuchi Y
Gastroenterol Jpn; 1989 Apr; 24(2):164-9. PubMed ID: 2744332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
